← Leaderboards
Richard Clinton Becker
Duke University
$11,111,515
Attributed
$11,111,515
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.5M · FY2012–16$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$22,223,030 · 8
By mechanism
U54$22,223,030 · 8
Top collaborators
- Bruce Alan Sullenger5 shared
Most similar at Duke University
Same institution · by research overlap
- Peter K Smith$5,027,299
- Kenneth A Dodge$42,207,577
- Debara L Tucci$4,132,482
- Joel D Mainland$9,751,049
- Gary M Felker$17,096,538
Others in their field
Top investigators on “Hemostatic Agents”
- Susan Fera Assmann · New England Research Institutes, Inc.$27,762,151
- Erik Ian Tucker · Aronora, Inc.$19,952,885
- David Couper · Univ Of North Carolina Chapel Hill$17,635,956
- Mortimer Poncz · University Of Pennsylvania$17,093,276
- Kathryn M Anastos · Montefiore Medical Center (Bronx, Ny)$15,465,311
- James H. Morrissey · University Of Oklahoma Hlth Sciences Ctr$13,632,092
Research focus
Hemostatic AgentsBaseLaboratoriesSafetyResourcesCoagulation ProcessMonitorProgramsTranslational ResearchClinical ResearchHemostatic FunctionBlood VesselsPreventThrombosisResearch PersonnelLeadershipMeetingsAptamerOperative Surgical ProceduresAntidotesResearch Project GrantsBlood PlateletsHeparinClinically Relevant
Grant awards (40)
DTMI-Center for Thrombotic and Hemostatic Disorders$2,215,887
U54 · FY2016 · HL
MOLECULAR SYNTHESIS AND CHARACTERIZATION CORE (MSCC)$596,055
U54 · FY2016 · HL · contact PI
DEVELOPING A TRANSLATABLE PLATFORM FOR REVERSIBLE PLATELET INHIBITION$497,545
U54 · FY2016 · HL · contact PI
LABORATORY ASSESSMENT OF TARGETED ANTITHROMBOTIC THERAPIES$325,521
U54 · FY2016 · HL · contact PI
POTENTIAL OF A NOVEL ANTI-PLATELET APTAMER IN OPTIMIZING ANTITHROMBOTIC$249,153
U54 · FY2016 · HL · contact PI
Administrative Coordinating Center$212,333
U54 · FY2016 · HL · contact PI
ADMINISTRATAIVE CORE$204,898
U54 · FY2016 · HL · contact PI
Translational Research Skills Development Core (TRSDC): Training Future Generati$130,382
U54 · FY2016 · HL · contact PI
DTMI-Center for Thrombotic and Hemostatic Disorders$2,213,927
U54 · FY2015 · HL
DEVELOPING A TRANSLATABLE PLATFORM FOR REVERSIBLE PLATELET INHIBITION$791,418
U54 · FY2015 · HL · contact PI
LABORATORY ASSESSMENT OF TARGETED ANTITHROMBOTIC THERAPIES$319,943
U54 · FY2015 · HL · contact PI
POTENTIAL OF A NOVEL ANTI-PLATELET APTAMER IN OPTIMIZING ANTITHROMBOTIC$273,462
U54 · FY2015 · HL · contact PI
MOLECULAR SYNTHESIS AND CHARACTERIZATION CORE (MSCC)$241,757
U54 · FY2015 · HL · contact PI
Administrative Coordinating Center$211,656
U54 · FY2015 · HL · contact PI
ADMINISTRATAIVE CORE$200,082
U54 · FY2015 · HL · contact PI
Translational Research Skills Development Core (TRSDC): Training Future Generati$175,609
U54 · FY2015 · HL · contact PI
DTMI-Center for Thrombotic and Hemostatic Disorders$2,269,092
U54 · FY2014 · HL
DEVELOPING A TRANSLATABLE PLATFORM FOR REVERSIBLE PLATELET INHIBITION$988,426
U54 · FY2014 · HL · contact PI
LABORATORY ASSESSMENT OF TARGETED ANTITHROMBOTIC THERAPIES$324,012
U54 · FY2014 · HL · contact PI
POTENTIAL OF A NOVEL ANTI-PLATELET APTAMER IN OPTIMIZING ANTITHROMBOTIC$262,531
U54 · FY2014 · HL · contact PI
Administrative Coordinating Center$222,351
U54 · FY2014 · HL · contact PI
MOLECULAR SYNTHESIS AND CHARACTERIZATION CORE (MSCC)$213,812
U54 · FY2014 · HL · contact PI
Translational Research Skills Development Core (TRSDC): Training Future Generati$155,728
U54 · FY2014 · HL · contact PI
ADMINISTRATAIVE CORE$102,232
U54 · FY2014 · HL · contact PI
DTMI-Center for Thrombotic and Hemostatic Disorders$2,206,682
U54 · FY2013 · HL
DEVELOPING A TRANSLATABLE PLATFORM FOR REVERSIBLE PLATELET INHIBITION$924,187
U54 · FY2013 · HL · contact PI
LABORATORY ASSESSMENT OF TARGETED ANTITHROMBOTIC THERAPIES$315,491
U54 · FY2013 · HL · contact PI
POTENTIAL OF A NOVEL ANTI-PLATELET APTAMER IN OPTIMIZING ANTITHROMBOTIC$276,067
U54 · FY2013 · HL · contact PI
MOLECULAR SYNTHESIS AND CHARACTERIZATION CORE (MSCC)$231,190
U54 · FY2013 · HL · contact PI
Administrative Coordinating Center$216,411
U54 · FY2013 · HL · contact PI
Translational Research Skills Development Core (TRSDC): Training Future Generati$148,252
U54 · FY2013 · HL · contact PI
ADMINISTRATAIVE CORE$95,084
U54 · FY2013 · HL · contact PI
DTMI-Center for Thrombotic and Hemostatic Disorders$2,205,927
U54 · FY2012 · HL · contact PI
ADMINISTRATAIVE CORE$315,133
U54 · FY2012 · HL · contact PI
LABORATORY ASSESSMENT OF TARGETED ANTITHROMBOTIC THERAPIES$315,133
U54 · FY2012 · HL · contact PI
DEVELOPING A TRANSLATABLE PLATFORM FOR REVERSIBLE PLATELET INHIBITION$315,133
U54 · FY2012 · HL · contact PI
POTENTIAL OF A NOVEL ANTI-PLATELET APTAMER IN OPTIMIZING ANTITHROMBOTIC$315,133
U54 · FY2012 · HL · contact PI
MOLECULAR SYNTHESIS AND CHARACTERIZATION CORE (MSCC)$315,132
U54 · FY2012 · HL · contact PI
Translational Research Skills Development Core (TRSDC): Training Future Generati$315,132
U54 · FY2012 · HL · contact PI
Administrative Coordinating Center$315,131
U54 · FY2012 · HL · contact PI